- Home
- AQST
as 10-06-2025 10:30am EST
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | WARREN |
| Market Cap: | 390.4M | IPO Year: | 2018 |
| Target Price: | $10.29 | AVG Volume (30 days): | 3.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.69 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.12 - $6.43 | Next Earning Date: | 11-03-2025 |
| Revenue: | $44,132,000 | Revenue Growth: | -24.38% |
| Revenue Growth (this year): | -20.35% | Revenue Growth (next year): | 51.50% |
Stock Insider Trading Activity of Aquestive Therapeutics Inc. (AQST)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Barber Daniel | AQST | President and CEO | Sep 26 '25 | Sell | $6.03 | 91,343 | $551,191.06 | 923,430 | |
| Boyd Peter E. | AQST | See Remarks | Sep 26 '25 | Sell | $6.30 | 10,000 | $63,000.00 | 278,323 | |
| Barber Daniel | AQST | President and CEO | Sep 19 '25 | Sell | $6.00 | 400 | $2,400.00 | 923,430 | |
| Boyd Peter E. | AQST | See Remarks | Sep 5 '25 | Sell | $5.30 | 15,000 | $79,500.00 | 278,323 | |
| Jung Cassie | AQST | Chief Operating Officer | Sep 4 '25 | Sell | $5.00 | 62,180 | $310,900.00 | 283,346 |
Latest Aquestive Therapeutics Inc. News
AQST Breaking Stock News: Dive into AQST Ticker-Specific Updates for Smart Investing
MT Newswires
3 months ago
Sector Update: Health Care Stocks Mixed Premarket Tuesday
MT Newswires
3 months ago
Aquestive Therapeutics Says Canadian Regulator Has Granted Meeting to Discuss Anaphylm Approval
GlobeNewswire
3 months ago
Aquestive Therapeutics Provides International Expansion Update for Anaphylm™ (epinephrine) Sublingual Film
GlobeNewswire
3 months ago
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm™ (epinephrine) Sublingual Film at the CFAAR Food Allergy Summit
MT Newswires
4 months ago
Aquestive Gets FDA Acceptance of New Drug Application for Severe Allergic Reaction Treatment
GlobeNewswire
4 months ago
Aquestive Therapeutics Announces FDA Acceptance of New Drug Application and PDUFA Date for Anaphylm™ for the Treatment of Severe Allergic Reactions
Simply Wall St.
4 months ago
Those who invested in Aquestive Therapeutics (NASDAQ:AQST) three years ago are up 128%
Insider Monkey
4 months ago
Aquestive Therapeutics, Inc. (AQST): Analysts See 245% Upside Potential
Compare AQST vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AQST Aquestive Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.